To be fair, in Jan 2020, SP was ~$3. This was pending GvHD, CLBP and, CHF. Covid was not on the horizon at that time. GvHD had the highest probability of success and corresponding discount on analyst expectations. This one is somewhat on the backburner now. That leaves CHF and CLBP. The way I see it, CHF some see as a miss and others a goal, but it will probably go to VAR (FDA) and run the risk of being ruled offside. The only additional NEW upside potential we had since Jan was covid, and there is a risk that this will haemorrhage on the NASDAQ. Remember, when MSB first announced the Covid results/trial, the biggest response was on the NASDAQ. The initial response on the ASX was a bit muted and I am genuinely concerned that the reverse will happen tonight. So really, the only bullet we have left is the CLBP. In the short term, it's almost binary. If CLBP does not get through, I think we will see lows worse than post LVAD result. Because essentially, we will be in a worse position with trials and cashflow.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Update on COVID-19 ARDS Trial
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-382
-
-
- There are more pages in this discussion • 694 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.19 |
Change
-0.005(0.42%) |
Mkt cap ! $1.370B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.18 | $2.487M | 2.082M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 24693 | $1.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 7200 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 35325 | 1.180 |
13 | 75582 | 1.175 |
13 | 123366 | 1.170 |
6 | 130878 | 1.165 |
11 | 461925 | 1.160 |
Price($) | Vol. | No. |
---|---|---|
1.185 | 1855 | 2 |
1.190 | 37542 | 11 |
1.195 | 80990 | 14 |
1.200 | 74138 | 13 |
1.205 | 33925 | 4 |
Last trade - 11.39am 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |